DigitalBridge (NYSE:DBRG) and Crestview Partners have completed their $1.5 billion take-private acquisition of WideOpenWest (WOW!), concluding the transaction on December 31, 2025.
FibroBiologics (NASDAQ:FBLG) took a decisive step toward clinical-stage operations on Wednesday, filing an Investigational New Drug (IND) application with the U.S. Food and Drug Administration to begin Phase 1/2 trials for its lead psoriasis candidate, CYPS317.
SOL Strategies (NASDAQ: STKE) reported full-year financial results for the fiscal year ended September 30, 2025, posting revenue of CAD$14.5 million, a 36.7% increase year over year, driven primarily by the expansion of its staking and validator operations within the Solana ecosystem.
TransDigm Group (NYSE:TDG) has entered into a definitive agreement to acquire Stellant Systems for approximately $960 million in cash, marking a significant expansion of its highly engineered aerospace and defense component portfolio.
Taylor Devices (NASDAQ:TAYD) reported record-breaking financial results for the second quarter of fiscal 2026, as the North Tonawanda-based manufacturer leveraged strong demand from the aerospace and defense sectors to overcome broader economic pressures in its structural and industrial markets.
Sonim Technologies (NASDAQ:SONM) is set to abandon its decades-long history in the rugged mobile device market following shareholder approval of an asset purchase agreement with NEXA (formerly Social Mobile).
US spot Bitcoin ETFs recorded $355 million in net inflows, ending a seven-trading-day outflow streak.
Corcept Therapeutics (NASDAQ:CORT) shares plunged Wednesday after the U.S. Food and Drug Administration (FDA) rejected its New Drug Application (NDA) for relacorilant, a treatment for hypertension caused by excessive cortisol levels.
Beijing has demanded an immediate halt to US arms sales to Taiwan, warning the moves are driving the Taiwan Strait closer to conflict.
China Natural Resources (NASDAQ:CHNR) saw its net loss widen in the first half of 2025, even as the company aggressively cut overhead and continued exploration at its lead-silver mine in Inner Mongolia.
Axsome Therapeutics (NASDAQ:AXSM) shares edged higher Wednesday after the U.S. Food and Drug Administration (FDA) granted Priority Review to its supplemental New Drug Application (sNDA) for AXS-05, a treatment targeting the pervasive and distressing agitation associated with Alzheimer’s disease.
Axsome Therapeutics (NASDAQ:AXSM) is poised to file for U.S. regulatory approval of its narcolepsy treatment, AXS-12, following a successful pre-New Drug Application (NDA) meeting with the Food and Drug Administration.
